

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

VOLUNTARY ANNOUNCEMENT

Acquisition of partial equity interest in MICRON in Japan by a wholly-owned subsidiary

This announcement is voluntarily made by Tigermed Consulting Co., Ltd. (the “**Company**”) to inform the shareholders and potential investors of the Company about the latest business development of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that Tigermed Japan Co., Ltd. (“**Tigermed Japan**”), a wholly-owned subsidiary of the Company, has entered into a share transfer agreement with the former shareholders of MICRON/株式会社マイクロン (“**MICRON**”) in Japan to acquire a portion of their equity interest in MICRON. Upon completion of the transfer, Tigermed Japan will hold 56.37% of the equity interest in MICRON.

MICRON was founded in 2005 and is headquartered in Tokyo, Japan. With over 160 employees, MICRON is a CRO company specializing in medical imaging and clinical trial services. As the first CRO specializing in image analysis in Japan, MICRON has established a strong reputation in the field of clinical research in Japan with its outstanding technical capabilities and unique practices in image biomarkers and AI image support. It has won the long-term trust and praise of its customers and was shortlisted for the All Japan Best Contract Research Organization Award in 2024. With its extensive experience in clinical research and one of the largest imaging teams in Asia, it has provided relevant services to more than 250 customers and helped launching more than 40 products successfully over the past 20 years.

MICRON's core business is image analysis, and its main customers are domestic and foreign pharmaceutical companies in Japan. It also engages in other related businesses, such as clinical monitoring, clinical trial PM-related services, full life cycle services for medical imaging diagnosis software (SaMD), and medical device sales.

As of May 31, 2025, MICRON's total assets were JPY780.9476 million, the net assets were JPY-451.7517 million. From January to May 2025, the Company's revenue from main business was JPY939.5978 million, with a net loss of 67.0474 million JPY. (The above data has not been audited).

I. Overview of the Share Purchase

1. Tigermed Japan, a wholly-owned subsidiary of the Company, acquired 56.37% of MICRON's equity interest for a total purchase price of JPY484 million, equivalent to approximately RMB23.4771 million.
2. Currently, MICRON has no affiliate relationship with the Company, its controlling shareholders, actual controllers, directors, supervisors, or senior management, and MICRON does not currently hold any shares of the Company, either directly or indirectly. The Company's controlling shareholders, actual controllers, shareholders holding more than 5% of the shares, directors, supervisors, and senior management do not hold any shares of MICRON. According to the "Listing Rules of the Shenzhen Stock Exchange for Growth Enterprise Market Stocks", Tigermed Japan's purchase of partial MICRON's equity interest does not constitute a connected transaction.
3. In accordance with the Company's "Equity Investment Management System," this investment is authorized by the Board and approved by the Chairman.
4. This external investment does not constitute a major assets restructuring as stipulated under the "Administrative Measures for Major Assets Restructuring of Listed Companies", and is not subject to the approval of the relevant authorities.
5. As none of the applicable percentage ratios (as defined in Rule 14.07 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Hong Kong Listing Rules**")) in respect of the investment amounts to 5% or more, the investment does not constitute a notifiable transaction for the Company under Chapter 14 of the Hong Kong Listing Rules.

II. Main Contents of the Transaction

1. Tigermed Japan acquired 56.37% of MICRON's shares for a total purchase price of JPY484 million, equivalent to approximately RMB23.4771 million;
2. The MICRON shareholdings before and after this investment are as follows:

Name of Shareholders	Shareholding before the transaction		Shareholding after the transaction	
Ce Holdings	1,741	85.30%	681	33.33%
Suzuki Hiroaki	200	9.80%	160	7.84%
Toshihiro Miyachi	100	4.90%	50	2.45%
Tigermed Japan	0	0	1,150	56.37%
Total	2,041	100.00%	2,041	100.00%

3. The proposed completion date for this transaction is July 29, 2025.

III. The pricing policy and pricing basis of the transaction

The quantity of MICRON shares is 2,041 shares, and the transaction price is JPY376,000 per share. The transaction price was determined through consultation between both parties based on comparable transaction prices for similar transactions, and there is no harm to the interests of the Company or its shareholders.

IV. The purpose of the transaction and its impact on the listed company

After the completion of this transaction, with the help of MICRON's deep roots and customer resources in the Japanese market, it will be beneficial for the Company to further expand its business layout in Japan and the Asia-Pacific region. At the same time, both parties can achieve in-depth integration of technology and talent, and enhance their comprehensive competitiveness in the field of medical imaging and clinical services. This will have a positive impact on the Company's future operations, and is in line with the interests of all shareholders of the Company.

Shareholders and potential investors are advised to exercise caution in dealing in shares of the Company.

By Order of the Board
HANGZHOU TIGERMED CONSULTING CO., LTD.

Chairman
Dr. Ye Xiaoping

Hong Kong, July 28, 2025

As at the date of this announcement, the executive directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Mr. Wu Hao and Mr. Wen Zengyu; the independent non-executive Directors of the Company are Mr. Liao Qiyu, Mr. Yuan Huagang and Ms. Liu Yuwen.